Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser device aims to lower eye pressure better in glaucoma surgery trial

NCT ID NCT06246136

Disease control Sponsor: Elios Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two devices used during cataract surgery to treat open-angle glaucoma. About 194 adults with mild to moderate glaucoma and cataracts will receive either the ELIOS device or a competitor device. The main goal is to see which one lowers eye pressure more effectively after 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 194 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female subjects. 2. 40 years old or older. 3. Diagnosis of mild to moderate primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma: 4. Visually significant cataract eligible for phacoemulsification. Exclusion Criteria: 1. All forms of angle closure glaucoma 2. Secondary glaucoma, including traumatic, neovascular, uveitic, lens-induced, steroid-induced, angle-recession, glaucoma associated with vascular disorders, and glaucoma associated with increased episcleral venous pressure 3. Congenital or developmental glaucoma 4. Prior incisional glaucoma surgery, intraocular surgery or ocular laser treatment of any type with the exception of selective laser trabeculoplasty (SLT) occurring a minimum of 6 months prior to the Screening visit

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ELIOS Clincal Site

    RECRUITING

    Madrid, Spain

  • ELIOS Clinical Site

    RECRUITING

    Leuven, Belgium

  • ELIOS Clinical Site

    RECRUITING

    Bordeaux, France

  • ELIOS Clinical Site

    RECRUITING

    Bochum, Germany

  • ELIOS Clinical Site

    RECRUITING

    Maastricht, Netherlands

  • ELIOS Clinical Site

    RECRUITING

    East Grinstead, United Kingdom

  • ELIOS Clinical Site

    RECRUITING

    Edinburgh, United Kingdom

  • ELIOS Clinical Site

    RECRUITING

    Guildford, United Kingdom

  • ELIOS Clinical Site

    RECRUITING

    Manchester, United Kingdom

  • ELIOS Clinical site

    RECRUITING

    Madrid, Spain

  • ELIOS clinical site

    RECRUITING

    Paris, France

  • ELIOS clinical site

    RECRUITING

    Heidelberg, Germany

  • ELIOS clinical site

    RECRUITING

    Barcelona, Spain

  • ELIOS clinical site

    RECRUITING

    London, United Kingdom

  • Elios Clinical Site

    RECRUITING

    Avranches, France

  • Elios clinical site

    RECRUITING

    Bonn, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.